Stay updated on REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial

Sign up to get notified when there's something new on the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Revision label updated from v3.3.1 to v3.3.2 in the page footer. This is a minor maintenance update and does not affect study information.
    Difference
    0.0%
    Check dated 2025-12-01T17:26:53.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    A new revision label 'Revision: v3.3.1' was added and the previous 'Revision: v3.2.0' label was removed.
    Difference
    0.0%
    Check dated 2025-11-24T14:36:24.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    A government funding/operating status notice was removed from the page; the study details and contact information remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-11-17T06:54:21.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    There are no significant additions or deletions to core page content; the page appears to retain the same sections such as Study Overview, Eligibility Criteria, Study Plan, and Contacts/Locations, with only minor visual adjustments. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-11-03T01:17:56.000Z thumbnail image
  6. Check
    71 days ago
    Change Detected
    Summary
    Update includes a critical operating status notice and a new software version (v3.2.0), indicating updated deployment with potential service impact; previous version reference (v3.1.0) was removed.
    Difference
    4%
    Check dated 2025-10-05T10:19:45.000Z thumbnail image
  7. Check
    79 days ago
    Change Detected
    Summary
    - Added Revision: v3.1.0. - Removed several MedlinePlus topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) and an older Revision: v3.0.2. The page now updates its version and omits multiple drug-safety-related topics.
    Difference
    0.6%
    Check dated 2025-09-28T03:19:59.000Z thumbnail image

Stay in the know with updates to REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page.